SAB Biotherapeutics Inc
NASDAQCM:SABS
United States / Healthcare / Biotechnology
Exchange Data
Hide this widget
Price
1.48 USD
Day change
-0.07 (-4.52%)
52-week range
1.45 - 5.01
Closed
Summary of SAB Biotherapeutics Inc
Hide this widget
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to ...
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Year
10 Years
- (-)
Data Explorer
Hide this widget
Data could not be retrieved
Peer Benchmarks
In the News
Hide this widget
Fair Value
Hide this widget
Average
–
Upside
–
Uncertainty
–
Spread
–
Financial Health
Health Details
Hide this widget
Financial Health for SAB Biotherapeutics is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.
12345
Financial Models for SAB Biotherapeutics Inc
Model Gallery
Hide this widget
| DuPont ROE AnalysisView Updated 22 hours ago |
| 10Y Historical FinancialsView Updated 22 hours ago |
| 5Y Historical FinancialsView Updated 22 hours ago |
| EV / EBIT MultiplesView Updated 16 hours ago |
| P/E MultiplesView Updated 16 hours ago |
| Price / Book MultiplesView Updated 16 hours ago |
| Price / Sales MultiplesView Updated 16 hours ago |
| EV / Revenue MultiplesView Updated 16 hours ago |
| 10Y DCF EBITDA ExitView Updated 16 hours ago |
| 10Y DCF Revenue ExitView Updated 16 hours ago |
| 10Y DCF Growth ExitView Updated 16 hours ago |
| 5Y DCF EBITDA ExitView Updated 16 hours ago |
| 5Y DCF Revenue ExitView Updated 16 hours ago |
| 5Y DCF Growth ExitView Updated 16 hours ago |
| Earnings Power ValueView Updated 16 hours ago |
| EV / EBITDA MultiplesView Updated 16 hours ago |
| CAPM WACC ModelView Updated 11 hours ago |
Historical Financials
Full Financials
Hide this widget
| (USD in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Sep-24 | Sep-23 | Sep-24 |
| Income Statement | |||||
| Revenue | 24 | 2.24 | 1.51 | 1.27 | 0.00 |
| Operating Income | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Net Profit | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Diluted EPS | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| EBITDA | |||||
| Balance Sheet | |||||
| Cash & ST Invest. | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Assets | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Current Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Liabilities | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Equity | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Total Debt | 5.93 | 5.91 | 4.52 | 4.65 | 4.52 |
| Cash Flow Statement | |||||
| Cash Flow Operations | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Investing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Cash From Financing | InvPro+ | InvPro+ | InvPro+ | InvPro+ | InvPro+ |
| Free Cash Flow | (26) | (25) | (39) | (5.25) | (6.39) |
Analyst Notes
March 29, 2025
Hide this widget